Compare M&T Bank Corporation (MTB) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs ResMed Inc. — how do they compare? M&T Bank Corporation trades at $222.43 (market cap $31.28B), while ResMed Inc. trades at $227.51 (market cap $31.78B). The key difference: M&T Bank Corporation and ResMed Inc. are close in size by market cap, and M&T Bank Corporation pays the higher dividend (2.77%). Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and ResMed Inc. for 51 Days on average.
| MTB | RMD | |
|---|---|---|
Market Cap | $31.28B | $31.78B |
Volume | 934,561 | 1,128,382 |
Sector | Financials | Health |
52-Week High | $254.09 | $277.88 |
52-Week Low | $178.63 | $182.82 |
Typical Hold Time | 100 Days | 51 Days |
Enterprise Value | $47.64B | $31.14B |
Dividend Yield | 2.77% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $217.56, down 0.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows solid fundamentals with a P/E of 11.47, net income margin of 30.85%, and consistent earnings beats in recent quarters. Recent news highlights dividend strength, branch expansion, and AI-driven growth initiatives.
The stock offers a compelling value proposition with a consensus price target of $258.92 (18.9% upside), supported by loan growth and efficiency gains. Key risks include interest rate sensitivity and macroeconomic pressures. Analyst sentiment is mixed, with 31% buy ratings but a majority hold stance, reflecting cautious optimism amid a challenging rate environment.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
